Published in BMC Cancer on March 09, 2016
Databases and tools for constructing signal transduction networks in cancer. BMB Rep (2017) 0.75
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature (2012) 31.78
A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell (2006) 27.36
Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med (1998) 25.41
THE TWO HISTOLOGICAL MAIN TYPES OF GASTRIC CARCINOMA: DIFFUSE AND SO-CALLED INTESTINAL-TYPE CARCINOMA. AN ATTEMPT AT A HISTO-CLINICAL CLASSIFICATION. Acta Pathol Microbiol Scand (1965) 22.65
Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal (2013) 19.54
The Cancer Genome Atlas Pan-Cancer analysis project. Nat Genet (2013) 11.29
Cancer drug resistance: an evolving paradigm. Nat Rev Cancer (2013) 6.77
Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology (2008) 5.31
Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery. PLoS One (2009) 4.62
Circumventing cancer drug resistance in the era of personalized medicine. Cancer Discov (2012) 3.25
Molecular mechanisms underlying ErbB2/HER2 action in breast cancer. Oncogene (2000) 3.12
Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer. J Clin Oncol (1990) 3.12
Cancer immunology--analysis of host and tumor factors for personalized medicine. Nat Rev Clin Oncol (2011) 2.90
Tumor heterogeneity and personalized medicine. N Engl J Med (2012) 2.63
Biology of HER2 and its importance in breast cancer. Oncology (2001) 2.54
Mouse xenograft models vs GEM models for human cancer therapeutics. Dis Model Mech (2008) 2.37
HER2 expression in gastric cancer: Rare, heterogeneous and of no prognostic value - conclusions from 924 cases of two independent series. Cell Oncol (2010) 1.93
Dual mTORC1/2 and HER2 blockade results in antitumor activity in preclinical models of breast cancer resistant to anti-HER2 therapy. Clin Cancer Res (2012) 1.65
HER2/neu gene amplification and protein overexpression in gastric and gastroesophageal junction adenocarcinoma: a review of histopathology, diagnostic testing, and clinical implications. Arch Pathol Lab Med (2012) 1.62
Cancer cell lines for drug discovery and development. Cancer Res (2014) 1.60
A monoclonal antibody against the c-erbB-2 protein enhances the cytotoxicity of cis-diamminedichloroplatinum against human breast and ovarian tumor cell lines. Cancer Res (1991) 1.58
Molecular characteristics of eight gastric cancer cell lines established in Japan. Pathol Int (2000) 1.54
Antitumor activity of trastuzumab in combination with chemotherapy in human gastric cancer xenograft models. Cancer Chemother Pharmacol (2006) 1.51
The UCSC Cancer Genomics Browser: update 2015. Nucleic Acids Res (2014) 1.44
HER2 as a prognostic factor in breast cancer. Oncology (2001) 1.43
HER2-positive gastric cancer. Gastric Cancer (2013) 1.32
AMPKα modulation in cancer progression: multilayer integrative analysis of the whole transcriptome in Asian gastric cancer. Cancer Res (2012) 1.31
Lung cancer cell lines: Useless artifacts or invaluable tools for medical science? Lung Cancer (2010) 1.30
HER2 gene amplification in breast cancer: a rogues' gallery of challenging diagnostic cases: UKNEQAS interpretation guidelines and research recommendations. Am J Clin Pathol (2012) 1.29
Combined EGFR/MET or EGFR/HSP90 inhibition is effective in the treatment of lung cancers codriven by mutant EGFR containing T790M and MET. Cancer Res (2012) 1.27
Monoclonal antibodies directed to the erbB-2 receptor inhibit in vivo tumour cell growth. Br J Cancer (1993) 1.21
Patient-derived xenografts of non small cell lung cancer: resurgence of an old model for investigation of modern concepts of tailored therapy and cancer stem cells. J Biomed Biotechnol (2012) 1.14
Prediction of gastric cancer development by serum pepsinogen test and Helicobacter pylori seropositivity in Eastern Asians: a systematic review and meta-analysis. PLoS One (2014) 1.04
Co-expression of heparin-binding EGF-like growth factor and related peptides in human gastric carcinoma. Int J Cancer (1996) 1.03
Growth inhibitory effects of trastuzumab and chemotherapeutic drugs in gastric cancer cell lines. Cancer Lett (2004) 0.99
HER-2 amplification is highly homogenous in gastric cancer. Hum Pathol (2009) 0.99
Targeting the vascular endothelial growth factor pathway in the treatment of human malignancy. Immunol Invest (2007) 0.99
Epidermal growth factor receptor inhibitors: coming of age. Cancer Control (2014) 0.98
HNF4α is a therapeutic target that links AMPK to WNT signalling in early-stage gastric cancer. Gut (2014) 0.95
Personalized medicine: risk prediction, targeted therapies and mobile health technology. BMC Med (2014) 0.95
Use of protein array to investigate receptor tyrosine kinases activated in gastric cancer. Int J Oncol (2010) 0.89
Personalized oncology: genomic screening in phase 1. APMIS (2014) 0.89
PATHOME: an algorithm for accurately detecting differentially expressed subpathways. Oncogene (2014) 0.89
Chromosomal and microsatellite instability in sporadic gastric cancer. J Gastroenterol Hepatol (2004) 0.88
Establishment and characterization of six human gastric carcinoma cell lines, including one naturally infected with Epstein-Barr virus. Cell Oncol (Dordr) (2012) 0.83
Combined inhibition of AKT/mTOR and MDM2 enhances Glioblastoma Multiforme cell apoptosis and differentiation of cancer stem cells. Sci Rep (2015) 0.82
Cell and tissue microarray technologies for protein and nucleic acid expression profiling. J Histochem Cytochem (2012) 0.79
Update on emerging treatments for chronic myeloid leukemia. Expert Opin Emerg Drugs (2015) 0.79
Adjuvant trastuzumab in early breast cancer. Ann Oncol (2006) 0.77